Text Size

Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2006 by Central Texas Veterans Health Care System.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Central Texas Veterans Health Care System
ClinicalTrials.gov Identifier:
NCT00290316
First received: February 10, 2006
Last updated: June 5, 2006
Last verified: January 2006
History of Changes
  Purpose

The diagnostic accuracy of EUS for detection of the liver tumors (primary and metastatic) remains unknown. To compare the accuracy of the EUS and CT scan for detection of the primary and metastatic carcinoma of the liver.


Condition Intervention Phase
Hepatocellular Carcinoma
Hepatoma
Cholangiocarcinoma
Liver Metastases
 Procedure: Endoscopy ultrasound
 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver – A Prospective Study

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Central Texas Veterans Health Care System:

Primary Outcome Measures:
  • To compare the accuracy of the EUS and CT scan for detection of the primary and metastatic carcinoma of the liver.

Secondary Outcome Measures:
  • Secondary:
  • Determine the diagnostic yield of fine needle aspiration using EUS (EUS-FNA) in patients with suspected liver metastasis on EUS examination.
  • Compare the accuracy of the PET scan with EUS for the detection of the liver metastases.
  • Determine the safety of EUS-FNA in subjects with liver lesions.
  • Impact of the EUS on the management of the hepatocellular carcinoma
  • 2.2.5 To study characteristic echoendoscopic findings of the primary and secondary liver tumor.

Study Start Date: July 2004
Estimated Study Completion Date: January 2006
  Show Detailed Description

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients with newly diagnosed colon, pancreatic, esophageal, lung, gastric cancer and patient with hepatitis C or B with elevated levels of alpha-fetoprotein or radiological findings suggestive of mass in the liver.

Exclusion Criteria:

  • Advanced heart or lung disease that precludes conscious sedation
  • Liver failure
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00290316

Locations
United States, Texas
Central Texas Veterans health Care System
Temple, Texas, United States, 76504
Sponsors and Collaborators
Central Texas Veterans Health Care System
Investigators
Principal Investigator: Pankaj Singh, MD Central Texas Veterans Health Care System
  More Information

No publications provided by Central Texas Veterans Health Care System

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00290316     History of Changes
Other Study ID Numbers: 0002
Study First Received: February 10, 2006
Last Updated: June 5, 2006
Health Authority: United States: Institutional Review Board

Keywords provided by Central Texas Veterans Health Care System:
Hepatocellular carcinoma
Cholangiocarcinoma
Metastasis
Liver neoplasm

Additional relevant MeSH terms:
Carcinoma
Liver Neoplasms
Carcinoma, Hepatocellular
Neoplasm Metastasis
Cholangiocarcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
 Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Adenocarcinoma
Neoplastic Processes
Pathologic Processes

ClinicalTrials.gov processed this record on May 19, 2013